Harlan Waksal - 09 Dec 2024 Form 4 Insider Report for Lyra Therapeutics, Inc. (LYRA)

Signature
/s/ Jason Cavalier, Attorney-in-Fact for Harlan Waksal
Issuer symbol
LYRA
Transactions as of
09 Dec 2024
Net transactions value
$0
Form type
4
Filing time
11 Dec 2024, 18:39:09 UTC
Previous filing
11 Jun 2024

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction LYRA Performance-based Restricted Stock Units Award $0 -128,333 -100% $0.000000 0 09 Dec 2024 Common Stock 128,333 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Each Performance-based Restricted Stock unit ("PSU") represented a contingent right to receive one share of the Issuer's common stock.
F2 On March 21, 2024, the Reporting Person was granted a PSU for an aggregate of up to 385,000 shares of common stock under the Issuer's 2020 Incentive Award Plan (the "Agreement"). Under the terms of the Agreement, the underlying PSUs will become earned upon certain milestone events. On December 9, 2024, the Issuer determined that Milestone 1 of the PSU was achieved, resulting in 128,333 PSUs being earned. The earned PSUs will vest on January 31, 2028. The PSUs have no expiration date.